Supplementary Data1 from ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor | Synapse
October 2, 2025Open Access
Supplementary Data1 from ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor
Key Points
ctDNA levels are evaluated as a potential biomarker for treatment response.
The trial involves patients with advanced gastrointestinal stromal tumor (GIST) to determine treatment efficacy.
Conclusions highlight the relevance of ctDNA in monitoring disease progression during treatment.
Further studies are suggested to validate ctDNA's role in personalized medicine approaches.